文献速递乳腺癌放疗

局部晚期乳腺癌术前放疗反应的分子特征

Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer.
PubMed 文献 · Radiat Oncol · 2018-10-01

该研究基于134例局部晚期乳腺癌(LABC)患者队列,利用Agilent 60K微阵列平台在23例FFPE肿瘤样本中建立基线转录谱,其中11例放疗前和3例放疗后样本通过质控用于下游分析,识别pRT反应差异相关基因,并在独立术前qRT-PCR子集(60例,42例合格)和术后Erasmus队列(344例淋巴结阴性乳腺癌患者,20%仅手术、80%手术加放疗)中验证。研究发现192个显著差异表达基因(FDR<0.10),APOA1、MAP3K4和MMP14在术前设置中差异表达(FDR<0.20),MAP3K4在术后设置中被验证为无远处转移生存的放疗特异性预测生物标志物(HR=2.54,95%CI:1.42-4.55,p=0.002)。

要点

  • 在局部晚期乳腺癌中识别出192个与术前放疗反应相关的差异表达基因(FDR<0.10)。
  • APOA1、MAP3K4和MMP14在术前放疗反应者与无反应者间差异表达(FDR<0.20)。
  • MAP3K4在术后设置中验证为无远处转移生存的放疗特异性预测标志物(HR=2.54,95%CI:1.42-4.55,p=0.002)。

核心结论

  • 本研究指出MAP3K4是术前和术后设置中放疗反应的推定生物标志物,也是放疗增敏联合治疗的潜在靶点,需进一步临床前研究和前瞻性临床验证。

研究设计与样本

  • 研究基于塞尔维亚肿瘤与放射学研究所(IORS)134例接受术前放疗且无既往或同期系统治疗的局部晚期乳腺癌患者队列。
  • 基线转录谱使用Agilent 60K微阵列平台在23例FFPE肿瘤样本中建立,其中11例放疗前和3例放疗后样本通过质控用于下游分析。
  • 使用Ingenuity Pathways Analysis软件识别差异放疗反应相关的生物网络和信号通路。
  • 候选基因的预测价值在独立术前qRT-PCR子集(60例LABC样本,42例质量合格用于数据分析)和术后设置(Erasmus队列344例淋巴结阴性乳腺癌患者,20%仅手术、80%手术加放疗的微阵列数据)中验证。

主要发现

  • 在术前放疗反应者与无反应者肿瘤间识别出192个显著差异表达基因(FDR<0.10),涉及细胞发育、生长和增殖调控、染色体复制细胞周期控制、葡萄糖代谢和NAD生物合成II途径。
  • APOA1、MAP3K4和MMP14基因在术前设置中放疗反应者与无反应者间差异表达(FDR<0.20)。
  • MAP3K4在术后设置中被进一步验证为无远处转移生存的放疗特异性预测生物标志物(HR=2.54,95%CI:1.42-4.55,p=0.002)。

关键数值与推荐

  • 差异表达基因筛选标准:FDR<0.10(192个基因)。
  • 候选基因术前差异表达标准:FDR<0.20(APOA1、MAP3K4、MMP14)。
  • MAP3K4与无远处转移生存关联:HR=2.54(95%CI:1.42-4.55),p=0.002。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步临床前研究和前瞻性临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation therapy is an indispensable part of various treatment modalities for breast cancer. Specifically, for non-inflammatory locally advanced breast cancer (LABC) patients, preoperative radiotherapy (pRT) is currently indicated as a second line therapy in the event of lack of response to neoadjuvant chemotherapy. Still approximately one third of patients fails to respond favourably to pRT. The aim of this study was to explore molecular mechanisms underlying differential response to radiotherapy (RT) to identify predictive biomarkers and potential targets for increasing radiosensitivity. METHODS: The study was based on a cohort of 134 LABC patients, treated at the Institute of Oncology and Radiology of Serbia (IORS) with pRT, without previous or concomitant systemic therapy. Baseline transcriptional profiles were established using Agilent 60 K microarray platform in a subset of 23 formalin-fixed paraffin-embedded (FFPE) LABC tumour samples of which 11 radiotherapy naïve and 3 post-radiotherapy samples passed quality control and were used for downstream analysis. Biological networks and signalling pathways underlying differential response to RT were identified using Ingenuity Pathways Analysis software. Predictive value of candidate genes in the preoperative setting was further validated by qRT-PCR in an independent subset of 60 LABC samples of which 42 had sufficient quality for data analysis, and in postoperative setting using microarray data from 344 node-negative breast cancer patients (Erasmus cohort, GSE2034 and GSE5327) treated either with surgery only (20%) or surgery with RT (80%). RESULTS: We identified 192 significantly differentially expressed genes (FDR < 0.10) between pRT-responsive and non-responsive tumours, related to regulation of cellular development, growth and proliferation, cell cycle control of chromosomal replication, glucose metabolism and NAD biosynthesis II route. APOA1, MAP3K4, and MMP14 genes were differentially expressed (FDR < 0.20) between pRT responders and non-responders in preoperative setting, while MAP3K4 was further validated as RT-specific predictive biomarker of distant metastasis free survival (HR = 2.54, [95%CI:1.42-4.55], p = 0.002) in the postoperative setting. CONCLUSIONS: This study pinpoints MAP3K4 as a putative biomarker of response to RT in both preoperative and postoperative settings and a potential target for radiosensitising combination therapy, warranting further pre-clinical studies and prospective clinical validation.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Tanić M, Krivokuća A, Čavić M, et al. Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer. Radiat Oncol. 2018. PMID: 30285791. doi:10.1186/s13014-018-1129-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。